NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its earnings results on Wednesday, November, 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.49. The company had revenue of $168 million for the quarter, compared to analysts' expectations of $152.47 million. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The firm's quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.03) earnings per share. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

12 analysts have issued 1 year price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $48.00 to $120.00. On average, they expect Ionis Pharmaceuticals' share price to reach $76.64 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ionis Pharmaceuticals.

Media coverage about IONS stock has been trending negative this week, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,480,000 shares, an increase of 10.1% from the December 15th total of 7,700,000 shares. Based on an average daily trading volume, of 989,100 shares, the short-interest ratio is presently 8.6 days. Approximately 6.6% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tocqueville Asset Management L.P. (0.29%), Scout Investments Inc. (0.18%), Peregrine Capital Management LLC (0.15%), Janney Montgomery Scott LLC (0.03%), Gateway Investment Advisers LLC (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.02%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Gateway Investment Advisers LLC, IFP Advisors Inc, Janney Montgomery Scott LLC, Raymond James Trust N.A., Arden Trust Co, Zurcher Kantonalbank Zurich Cantonalbank and IFM Investors Pty Ltd. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Peregrine Capital Management LLC, New England Research & Management Inc., Alpine Global Management LLC, Fulton Breakefield Broenniman LLC, Exchange Traded Concepts LLC, DNB Asset Management AS and Allred Capital Management LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $60.02.

Ionis Pharmaceuticals has a market capitalization of $8.44 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.